|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15191520152115221523152415251526152715281529...15771578» |
- Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Enrollment change, Trial primary completion date: Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=6, Completed, Sponsor: University of Vermont
Recruiting --> Completed | N=22 --> 6 | Trial primary completion date: Oct 2015 --> Apr 2015
- Stivarga (regorafenib) / Bayer
New P4 trial, Stroma, Metastases: The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (clinicaltrials.gov) - Jun 16, 2016
P4, N=14, Recruiting, Sponsor: Erasmus Medical Center
- sEphB4-HSA / VasGene, National Cancer Institute
New P2 trial: sEphB4-HSA in Treating Patients With Kaposi Sarcoma (clinicaltrials.gov) - Jun 16, 2016
P2, N=42, Suspended, Sponsor: AIDS Malignancy Consortium
- celecoxib oral / Generic mfg.
Trial completion, Trial primary completion date, Tumor cell: Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - Jun 15, 2016
P1, N=44, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=22 --> 6 | Trial primary completion date: Oct 2015 --> Apr 2015 Suspended --> Completed | Trial primary completion date: Nov 2017 --> Jun 2016
- | tasadenoturev (DNX-2401) / DNAtrix
New P2 trial: CAPTIVE: Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (clinicaltrials.gov) - Jun 15, 2016
P2, N=48, Active, not recruiting, Sponsor: DNAtrix, Inc.
- adavosertib (AZD1775) / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy: NCI-2014-00620: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 13, 2016
P2, N=100, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed | Trial primary completion date: Nov 2017 --> Jun 2016 Trial primary completion date: May 2016 --> Nov 2016
- Trial primary completion date, Metastases: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (clinicaltrials.gov) - Jun 13, 2016
P2, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2016 --> Nov 2016 Trial primary completion date: May 2016 --> Dec 2016
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 13, 2016
P1, N=19, Completed, Sponsor: University of Southern California
Trial primary completion date: May 2016 --> Dec 2016 Active, not recruiting --> Completed
- New trial: THEODORA: Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay (clinicaltrials.gov) - Jun 13, 2016
P=N/A, N=100, Not yet recruiting, Sponsor: Centre Leon Berard
- Zokinvy (lonafarnib) / Eiger
Trial primary completion date: Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide (clinicaltrials.gov) - Jun 11, 2016
P1, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- melanoma GVAX / Novartis
Enrollment change, Trial primary completion date, Tumor cell, Metastases: Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma (clinicaltrials.gov) - Jun 11, 2016
P1, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2016 --> Dec 2017 N=36 --> 12 | Trial primary completion date: Dec 2015 --> Jul 2006
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change, Trial termination: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors (clinicaltrials.gov) - Jun 11, 2016
P0, N=1, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=10 --> 1 | Recruiting --> Terminated; Very slow accrual; terminated to allow resources to be utilized more effectively on other studies. No data analysis completed, nor any conclusions reached.
- ||| Votrient (pazopanib) / Novartis, BeiGene
New P1 trial, Metastases: Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer (clinicaltrials.gov) - Jun 11, 2016
P1, N=51, Not yet recruiting, Sponsor: Virginia Commonwealth University
- Avastin (bevacizumab) / Roche
Enrollment open, Enrollment change, Metastases: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (clinicaltrials.gov) - Jun 11, 2016
P1, N=36, Recruiting, Sponsor: Mayo Clinic
No data analysis completed, nor any conclusions reached. Suspended --> Recruiting | N=18 --> 36
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Combination therapy: Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma (clinicaltrials.gov) - Jun 10, 2016
P2, N=85, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting | N=18 --> 36 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jun 2015
- | efatutazone (CS-7017) / Daiichi Sankyo
Enrollment closed, Surgery: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 10, 2016
P2, N=36, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jun 2015 Recruiting --> Active, not recruiting
- || Vigil (gemogenovatucel-T) / Gradalis
Trial primary completion date, Combination therapy, Tumor cell, Metastases: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma (clinicaltrials.gov) - Jun 9, 2016
P2b, N=62, Recruiting, Sponsor: Gradalis, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- temozolomide / Generic mfg.
Phase classification, IO biomarker: Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma (clinicaltrials.gov) - Jun 9, 2016
P1/2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P2 --> P1/2
- | bezuclastinib (PLX9486) / Cogent Biosci
Combination therapy, Stroma, Metastases: CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 9, 2016
P1b, N=92, Recruiting, Sponsor: Plexxikon
Phase classification: P2 --> P1/2 Phase classification: P1/2 --> P1b
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date, Surgery: A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery (clinicaltrials.gov) - Jun 9, 2016
P2, N=18, Recruiting, Sponsor: Oslo University Hospital
Phase classification: P1/2 --> P1b Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
New trial: TrObs: Retrospective Study of Trabectedin in Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 9, 2016
P=N/A, N=900, Not yet recruiting, Sponsor: Italian Sarcoma Group
- New trial: Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT (clinicaltrials.gov) - Jun 9, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na (clinicaltrials.gov) - Jun 9, 2016
P2, N=18, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- || Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
P1 data, Trial primary completion date: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Jun 5, 2016
P1, N=53, Active, not recruiting, Sponsor: Karyopharm Therapeutics, Inc
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Jun 2016 Trial primary completion date: Mar 2016 --> Jul 2016
- || Onureg (azacitidine oral) / BMS
Trial primary completion date: Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (clinicaltrials.gov) - Jun 5, 2016
P1, N=60, Recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Mar 2016 --> Jul 2016 Trial primary completion date: Jun 2016 --> Sep 2016
- || emactuzumab (RG7155) / SynOx Therap, Tecentriq (atezolizumab) / Roche
Enrollment change, Trial primary completion date, Metastases: A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 5, 2016
P1, N=162, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Sep 2016 N=97 --> 162 | Trial primary completion date: Mar 2018 --> Aug 2018
- temozolomide / Generic mfg.
Enrollment open, IO biomarker: Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma (clinicaltrials.gov) - Jun 5, 2016
P2, N=54, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=97 --> 162 | Trial primary completion date: Mar 2018 --> Aug 2018 Not yet recruiting --> Recruiting
- | Torisel (temsirolimus) / Pfizer
Enrollment open: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov) - Jun 5, 2016
P3, N=465, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Biomarker, New trial: NEOSarcomics: CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. (clinicaltrials.gov) - Jun 4, 2016
P=N/A, N=205, Not yet recruiting, Sponsor: Institut Bergoni
- ||||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial completion, Trial primary completion date, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 2, 2016
P3, N=640, Completed, Sponsor: Threshold Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Jun 1, 2016
P2, N=50, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2015 Trial primary completion date: Mar 2016 --> Mar 2018
- ||| padnarsertib (KPT-9274) / Karyopharm
Enrollment open, Metastases: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (clinicaltrials.gov) - Jun 1, 2016
P1, N=175, Recruiting, Sponsor: Karyopharm Therapeutics, Inc
Trial primary completion date: Mar 2016 --> Mar 2018 Not yet recruiting --> Recruiting
- ESP-01 / Esperas
Enrollment open, Phase classification, Combination therapy, Monotherapy, Metastases: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Jun 1, 2016
P1b/2a, N=93, Recruiting, Sponsor: Esperas Pharma Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2a
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, Metastases: RADIOSARP: A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (clinicaltrials.gov) - Jun 1, 2016
P1, N=41, Not yet recruiting, Sponsor: Institut Bergoni
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab in Treating Patients With Angiosarcoma (clinicaltrials.gov) - May 31, 2016
P2, N=30, Active, not recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1b/2a Trial primary completion date: Dec 2016 --> Dec 2017
- Seprehvir (HSV1716) / Sorrento
Enrollment change, Trial termination, Trial primary completion date, Surgery: Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery (clinicaltrials.gov) - May 31, 2016
P1, N=2, Terminated, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Dec 2016 --> Dec 2017 N=24 --> 2 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> May 2016
- New trial: Preoperative IMRT for Soft Tissue Sarcoma of the Extremities and Trunk: Low Rate of Wound Complications (clinicaltrials.gov) - May 31, 2016
P=N/A, N=67, Completed, Sponsor: Balgrist University Hospital
- pomalidomide / Generic mfg.
Clinical: Pomalidomide for Kaposi Sarcoma in People With or Without HIV (clinicaltrials.gov) - May 27, 2016
P1/2, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 2 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> May 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| crenigacestat (LY3039478) / Eli Lilly, BMS
New P1 trial, Combination therapy, Metastases: A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 27, 2016
P1, N=163, Not yet recruiting, Sponsor: Eli Lilly and Company
- | Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy (clinicaltrials.gov) - May 26, 2016
P3, N=220, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=300 --> 220 | Trial primary completion date: Oct 2016 --> Oct 2017
- Ibrance (palbociclib) / Pfizer, sunitinib / Generic mfg.
Trial primary completion date, Stroma, Metastases: CYCLIGIST: Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (clinicaltrials.gov) - May 26, 2016
P2, N=63, Recruiting, Sponsor: Institut Bergoni
Recruiting --> Active, not recruiting | N=300 --> 220 | Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Aug 2016 --> Aug 2017
- Enrollment change, Trial withdrawal, Trial primary completion date, Surgery: Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery (clinicaltrials.gov) - May 26, 2016
P1, N=0, Withdrawn, Sponsor: Blaze Bioscience Inc.
Trial primary completion date: Aug 2016 --> Aug 2017 N=21 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2016 --> May 2016
- New P2 trial: Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma (clinicaltrials.gov) - May 26, 2016
P2, N=41, Recruiting, Sponsor: Samsung Medical Center
- | Lartruvo (olaratumab) / Eli Lilly
New P1 trial, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - May 26, 2016
P1, N=40, Not yet recruiting, Sponsor: Eli Lilly and Company
- Trial primary completion date: Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI (clinicaltrials.gov) - May 25, 2016
P=N/A, N=50, Recruiting, Sponsor: Stanford University
N=21 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2016 --> May 2016 Trial primary completion date: Mar 2016 --> Dec 2017
- Trial completion: Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting (clinicaltrials.gov) - May 24, 2016
P=N/A, N=250, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Trial primary completion date: Mar 2016 --> Dec 2017 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Monotherapy, IO biomarker, Metastases: Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma (clinicaltrials.gov) - May 23, 2016
P2, N=26, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Trial primary completion date: Mar 2017 --> Oct 2017
- Trial termination, Surgery, Biopsy: EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma (clinicaltrials.gov) - May 23, 2016
P1, N=0, Terminated, Sponsor: University Health Network, Toronto
Trial primary completion date: Mar 2017 --> Oct 2017 Active, not recruiting --> Terminated; Lack of patient accrual
- ||| Varubi (rolapitant oral) / TerSera Therap, GSK
Enrollment change: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - May 23, 2016
P2, N=91, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Lack of patient accrual N=70 --> 91
- | TB-403 / Oxurion
Enrollment open: A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma (clinicaltrials.gov) - May 21, 2016
P1/2, N=36, Recruiting, Sponsor: Oncurious NV
N=70 --> 91 Not yet recruiting --> Recruiting